Coumarin Compounds with 6- or 7-(4-Aminobutynyloxy) Substituent: Synthesis, In Vitro Cytotoxicity and In Silico DNA Binding Studies

Molecules, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/molecules31183222
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Coumarin compounds are of great interest in drug development research. Various substituents on the coumarin core significantly influence its biological activity. Although a number of coumarins with specific biological properties have already been identified, the ongoing challenge lies in the design and synthesis of novel derivatives with high specificity for pharmacological targets. In this work, 6-(4-aminobut-2-ynyloxy)- and 7-(4-aminobut-2-ynyloxy)-substituted coumarin derivatives were designed and synthesized. As a method for the synthesis of 6- or 7-substituted coumarins (yields 26–98%), a copper-catalyzed one-pot three-component reaction (A3 coupling) of 6- or 7-(prop-2-ynyloxy)coumarins with formaldehyde and secondary amines was studied. In vitro biological testing (MTT assay) results showed that the new coumarins exhibit pronounced cytotoxicity against human cervical cancer (C33 A and CaSki) and breast cancer (MCF-7) cell lines, with activity being dependent on the substituent at the nitrogen atom in the side chain. The most active compounds inhibited tumor cell growth, with GI50 values of 4.3–9.4 μM (SI = 9.1–19.8). All new compounds demonstrated low cytotoxicity against the non-malignant epithelial VERO cells (GI50 > 86 μM). To understand the observed SAR trends, molecular modeling of the interaction between the new coumarin derivatives and DNA G-quadruplex binding sites was performed.